Metraipolis › archive › dc_034e21d3d633

Additive effects of GLY-200 (oral pharmacologic duodenal exclusion therapy) and GLP-1R agonist in obesity management — Europe PMC PMID:41270831

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41270831
DOI
10.1016/j.molmet.2025.102287
License (as archived)
solo-consultazione
Archived
2026-11-08T10:27:30.538Z
SHA-256 of the archived text
e2f4b9de2d25763e645b965e504498fa3ace172a3c9c5a4e2a2416b966d775b6
Stable URL of this page
https://metraipolis.com/documento/dc_034e21d3d633

How to cite

Additive effects of GLY-200 (oral pharmacologic duodenal exclusion therapy) and GLP-1R agonist in obesity management — Europe PMC PMID:41270831 — Europe PMC (en), https://europepmc.org/article/MED/41270831 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_034e21d3d633 (Metraipolis archive dc_034e21d3d633, sha256 e2f4b9de2d25763e645b965e504498fa3ace172a3c9c5a4e2a2416b966d775b6)
BibTeX
@misc{dc034e21d3d633,
  title = {Additive effects of GLY-200 (oral pharmacologic duodenal exclusion therapy) and GLP-1R agonist in obesity management — Europe PMC PMID:41270831},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41270831},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_034e21d3d633; sha256 e2f4b9de2d25763e645b965e504498fa3ace172a3c9c5a4e2a2416b966d775b6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41270831. Agents can read the archived copy with the MCP tool read_document.